Want to join the conversation?
According to $MRK, the company winning the breakthrough therapy designation and PRIME for its Ebola Zaire vaccine V920 indicate it has won the required approval to start the development & review of the drug candidate. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on early data.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.